As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Dyne Therapeutics, Inc. The largest reported stake is T. Rowe Price Investment Management, Inc.'s, at 18.7%. 15 filings are on record since August 7, 2025 (Schedule 13G/A, May 15, 2026).
Sell to companies like Dyne Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: JANUS HENDERSON GROUP Ltd. · Sole voting: 0 · Shared voting: 11,997,738 · Sole dispositive: 0 · Shared dispositive: 11,997,738 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Atlas Venture Fund XI, L.P. · Sole voting: 0 · Shared voting: 4,476,487 · Sole dispositive: 0 · Shared dispositive: 4,476,487 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Fmr LLC · Sole voting: 11,206,231 · Shared voting: 0 · Sole dispositive: 11,207,000 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-06
- · Reporting person: BlackRock, Inc. · Sole voting: 11,273,443 · Shared voting: 0 · Sole dispositive: 11,489,504 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-28
- · Holder: Janus Henderson Group Plc · Percent: 8.3% · SCHEDULE 13G/A
Dyne Therapeutics, Inc. has 15 Schedule 13D or 13G filings on record since 2025-08-07. 4 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 18.7% | 30,785,801 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| JANUS HENDERSON GROUP Ltd. | 7.3% | 11,997,738 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| BlackRock, Inc. | 7% | 11,489,504 | SCHEDULE 13G/A, 2026-07-28 | 2026-06-30 |
| Fmr LLC | 6.8% | 11,207,000 | SCHEDULE 13G/A, 2026-08-06 | 2026-06-30 |
| Atlas Venture Fund XI, L.P. | 2.4% | 4,476,487 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| RA Capital Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Dyne Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Dyne Therapeutics, Inc. and the records around it.
Dyne Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Atlas Venture Fund XI, L.P. also filed stake reports on 3 other companies: Korro Bio, Inc. (Aug 2026), Day One Biopharmaceuticals, Inc. (May 2026), SIONNA THERAPEUTICS, INC. (Oct 2025)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
Watch Dyne Therapeutics, Inc.
Get an email when Dyne Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Dyne Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Dyne Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dyne Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 0 | 11,997,738 | 0 | 11,997,738 | SCHEDULE 13G/A, 2026-08-13 |
| BlackRock, Inc. | 11,273,443 | 0 | 11,489,504 | 0 | SCHEDULE 13G/A, 2026-07-28 |
| Fmr LLC | 11,206,231 | 0 | 11,207,000 | 0 | SCHEDULE 13G/A, 2026-08-06 |
| Abigail P. Johnson | 0 | 0 | 11,207,000 | 0 | SCHEDULE 13G/A, 2026-08-06 |
| Atlas Venture Fund XI, L.P. | 0 | 4,476,487 | 0 | 4,476,487 | SCHEDULE 13G/A, 2026-08-13 |
| Atlas Venture Associates XI, L.P. | 0 | 4,479,449 | 0 | 4,479,449 | SCHEDULE 13G/A, 2026-08-13 |
| Atlas Venture Associates XI, LLC | 0 | 4,479,449 | 0 | 4,479,449 | SCHEDULE 13G/A, 2026-08-13 |
| Atlas Venture Opportunity Fund I, L.P. | 0 | 975,931 | 0 | 975,931 | SCHEDULE 13G/A, 2026-08-13 |
| Atlas Venture Associates Opportunity I, L.P. | 0 | 975,931 | 0 | 975,931 | SCHEDULE 13G/A, 2026-08-13 |
| Atlas Venture Associates Opportunity I, LLC | 0 | 975,931 | 0 | 975,931 | SCHEDULE 13G/A, 2026-08-13 |
| Atlas Venture Opportunity Fund II, L.P. | 0 | 1,344,719 | 0 | 1,344,719 | SCHEDULE 13G/A, 2026-08-13 |
| Atlas Venture Associates Opportunity II, L.P. | 0 | 1,344,719 | 0 | 1,344,719 | SCHEDULE 13G/A, 2026-08-13 |
| Atlas Venture Associates Opportunity II, LLC | 0 | 1,344,719 | 0 | 1,344,719 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Dyne Therapeutics, Inc. by CUSIP 26818M108 and gives its principal executive office as 1560 TRAPELO ROAD, WALTHAM, MA 02451 (SCHEDULE 13G/A, 2026-08-13).
What the percentages are based on
Each of the Fund XI Reporting Persons may be deemed to beneficially own 2.4% of the Issuer's outstanding Common Stock. Each of the Opportunity Fund Reporting Persons may be deemed to beneficially own 0.5% of the Issuer's outstanding Common Stock. Each of the Opportunity Fund II Reporting Persons may be deemed to beneficially own 0.7%, of the Issuer's outstanding Common Stock.Atlas Venture Fund XI, L.P., SCHEDULE 13G/A, 2026-08-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-07 | Janus Henderson Group Plc | 10.1% | SCHEDULE 13G/A |
| 2025-11-13 | Atlas Venture Fund XI, L.P. | 4% | SCHEDULE 13G/A |
| 2025-11-14 | RA Capital Management, L.P. | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 10.4% | SCHEDULE 13G/A |
| 2026-01-08 | T. Rowe Price Investment Management, Inc. | 10.7% | SCHEDULE 13G |
| 2026-02-17 | Janus Henderson Group Plc | 8.5% | SCHEDULE 13G/A |
| 2026-03-06 | T. Rowe Price Investment Management, Inc. | 16.2% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-06 | Fmr LLC | 5.4% | SCHEDULE 13G |
| 2026-05-15 | Janus Henderson Group Plc | 8.3% | SCHEDULE 13G/A |
| 2026-05-15 | T. Rowe Price Investment Management, Inc. | 18.7% | SCHEDULE 13G/A |
| 2026-07-28 | BlackRock, Inc. | 7% | SCHEDULE 13G/A |
| 2026-08-06 | Fmr LLC | 6.8% | SCHEDULE 13G/A |
| 2026-08-13 | JANUS HENDERSON GROUP Ltd. | 7.3% | SCHEDULE 13G/A |
| 2026-08-13 | Atlas Venture Fund XI, L.P. | 2.4% | SCHEDULE 13G/A |
Questions about who owns Dyne Therapeutics, Inc.
Who owns Dyne Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Dyne Therapeutics, Inc.: T. Rowe Price Investment Management, Inc. (18.7%, Schedule 13G/A, filed 2026-05-15), JANUS HENDERSON GROUP Ltd. (7.3%, Schedule 13G/A, filed 2026-08-13), BlackRock, Inc. (7%, Schedule 13G/A, filed 2026-07-28) and Fmr LLC (6.8%, Schedule 13G/A, filed 2026-08-06).
Who are the largest shareholders of Dyne Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Dyne Therapeutics, Inc. on this page are T. Rowe Price Investment Management, Inc. (18.7%), JANUS HENDERSON GROUP Ltd. (7.3%) and BlackRock, Inc. (7%).
When did T. Rowe Price Investment Management, Inc. buy into Dyne Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Investment Management, Inc. on this page is the Schedule 13G, filed 2026-01-08, reporting 10.7%; its latest, Schedule 13G/A filed 2026-05-15, reports 18.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 15 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Dyne Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 22, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Dyne Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.